Lilly, Novo lead as TD Cowen lifts GLP-1 sales forecast (LLY)

by


Feb. 22, 2025 1:39 PM ETEli Lilly and Company (LLY) Stock, NVO Stock, NONOF StockAMGN, AZN, REGN, ALT, VKTX, TERN, GPCR, MTSRBy: Dulan Lokuwithana, SA News Editor
Selection of weight loss drugs

Douglas Cliff

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating more than a 38% increase from its prior forecast.


Leave a Comment